Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma Final analysis of the phase II ‘proof-of-concept’ iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network

  C. Soussain ¹ AuthorId : 1341796
Author

  S. Choquet ² AuthorId : 983647
Author

  M. Blonski AuthorId : 11532839
Author

  D. Leclercq ² AuthorId : 1719232
Author

  C. Houillier ² AuthorId : 905393
Author

  K. Rezai ¹ AuthorId : 613756
Author

  F. Bijou ³ AuthorId : 1548660
Author

  R. Houot ⁴ AuthorId : 118376
Author

  E. Boyle AuthorId : 11118456
Author

  R. Gressin AuthorId : 464163
Author

  E. Nicolas-Virelizier ⁵ AuthorId : 11207925
Author

  M. Barrie ⁶ AuthorId : 1504223
Author

  C. Moluçon-Chabrot AuthorId : 11532840
Author

  M.L. Lelez AuthorId : 11532841
Author

  A. Clavert AuthorId : 751821
Author

  S. Coisy AuthorId : 11532842
Author

  S. Leruez AuthorId : 11532843
Author

  V. Touitou AuthorId : 1564568
Author

  N. Cassoux ¹ AuthorId : 11532844
Author

  M. Daniau ⁷ AuthorId : 11532845
Author

  M. Ertault de la Bretonnière ⁸ AuthorId : 11532846
Author

  A. El Yamani AuthorId : 11532847
Author

  H. Ghesquières ⁹ AuthorId : 11314385
Author

  K. Hoang-Xuan AuthorId : 905397
Author